OncoGenex Announces EMA Support for Phase 3 AFFINITY Trial Protocol Amendment

By: via Benzinga
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the European Medicines Agency (EMA) has completed its review of the ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.